ReviewBioMed research international2020
The Biomarkers for Acute Myocardial Infarction and Heart Failure.
Review in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed.
- Growth Differentiation Factor-15 in Acute Coronary Syndromes: Prognostic Value and Barriers to Clinical Implementation.International journal of molecular sciences · 2026Review
- Ultrasound-enabled refreshable electrochemical sensors for cardiac biomarker monitoring.Biosensors & bioelectronics · 2026Article
- Histochemical characterization of TDAG51 in endothelial remodeling and angiogenesis following myocardial infarctionEuropean journal of histochemistry : EJH · 2026Article
- Novel cardiac biomarkers (serum S100A12 (Calgranulin C), FSTL1 (Follistatin-like 1), and osteocalcin) in patients with acute chest pain.Journal of medical biochemistry · 2026Article
- A FRET Aptasensor Based on N-CQDs for Detection of Cardiac Troponin I in Acute Myocardial Infarction Diagnosis.International journal of nanomedicine · 2026Article
- Extracellular vesicles in heart failure: bridging pathogenic insights, diagnostic utility, and therapeutic applications.Frontiers in pharmacology · 2026Review
- Acute effects of marathon running on the heart: a systematic review and meta-analysis.BMJ open sport & exercise medicine · 2026Article
- A composite model incorporating systemic inflammatory burden and GRACE score for enhanced identification of elevated myocardial stress in acute myocardial infarction: an exploratory analysis.Frontiers in cardiovascular medicine · 2026Article
- Unveiling Heart Failure: Gender-Specific Insights and Innovations in Women's Cardiac Health.Current pharmaceutical design · 2026Review
- Endocan as a Novel Biomarker for Endothelial Dysfunction and Cardiovascular Prognosis in ST-Elevation Myocardial Infarction: A Contemporary Literature Review.Journal of personalized medicine · 2025Review
- Elevated Cardiac Troponin in Non-Cardiac Conditions Unrelated to Acute Myocardial Infarction.International journal of molecular sciences · 2025Review
- Advances in molecularly imprinted polymers for clinical biomarker detection (2021-2025).Mikrochimica acta · 2025Review
- Recent Advances in Micro- and Nano-Enhanced Intravascular Biosensors for Real-Time Monitoring, Early Disease Diagnosis, and Drug Therapy Monitoring.Sensors (Basel, Switzerland) · 2025Review
- Article
- Exploring the Diagnostic Utility of Serum Cofilin-1 and 2 Levels in Patients with Acute Coronary Syndrome: A Case-Control Pilot Study.Indian journal of clinical biochemistry : IJCB · 2025Article
- Cardiac Troponin I Biosensors: Innovations in Real-Time Diagnosis of Cardiovascular Diseases.Analytical science advances · 2025Review
- Review
- Serum Mitsugumin-53 Level as a Diagnostic Marker in Patients With Acute Coronary Syndrome: A Case-Control Study.Cureus · 2025Article
- Review
- The role of long non-coding RNA A2M-AS1 in early diagnosis and prognosis evaluation of acute myocardial infarction.Journal of cardiothoracic surgery · 2025Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of a large number of cardiovascular biomarkers, meant to complement the use of the electrocardiogram, echocardiography cardiac imaging, and clinical symptom assessment, has become a routine in clinical diagnosis, differential diagnosis, risk stratification, and prognosis and guides the management of patients with suspected cardiovascular diseases. There is a broad consensus that cardiac troponin and natriuretic peptides are the preferred biomarkers in clinical practice for the diagnosis of the acute coronary syndrome and heart failure, respectively, while the roles and possible clinical applications of several other potential biomarkers are still under study. This review mainly focuses on the recent studies of the roles and clinical applications of troponin and natriuretic peptides, which seem to be the best-validated markers in distinguishing and predicting the future cardiac events of patients with suspected cardiovascular diseases. Additionally, the review briefly discusses some of the large number of potential markers that may play a more prominent role in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.